Home / Business and Economy / Novo Nordisk and Emcure Team Up to Boost Access to Weight-Loss Drug in India
Novo Nordisk and Emcure Team Up to Boost Access to Weight-Loss Drug in India
10 Nov
Summary
- Novo Nordisk partners with Emcure to distribute weight-loss drug semaglutide in India
- Semaglutide to be launched under new brand name 'Poviztra' as a 2.4mg weekly injection
- Collaboration aims to enhance accessibility in India's fast-growing anti-obesity drug market
On November 10, 2025, Danish pharmaceutical company Novo Nordisk announced an exclusive partnership with Pune-based Emcure Pharmaceuticals to widely distribute its weight-loss therapy semaglutide in India. The two companies will launch semaglutide under a new brand name, Poviztra, as a 2.4mg weekly injection.
The move comes as competition heats up in India's fast-growing anti-obesity drug market. Last month, US drug giant Eli Lilly announced a similar tie-up with Mumbai-based Cipla to distribute its anti-obesity medication Tirzepatide. Novo Nordisk and Emcure have not yet revealed the pricing strategy or launch date for Poviztra, but have promised to be "very competitive" in their pricing.
